Skip to content

Circulating Tumor DNA Methylation Test to Differentiate Benign and Malignant Pulmonary Nodules

Multi-centers Validation of a Circulating Tumor DNA Assay to Differentiate Benign and Malignant Pulmonary Nodules Via Targeted High-throughput DNA Methylation Sequencing

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03181490
Enrollment
1490
Registered
2017-06-08
Start date
2017-06-08
Completion date
2019-05-31
Last updated
2020-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Nodule, Solitary

Keywords

Pulmonary Nodule, Solitary

Brief summary

Current state-of-the-art lung cancer early screening utilizes low-dose CT scan to identify lung nodules smaller than 3 cm in diameter. However, it's still a clinical challenge to differentiate between malignant and benign nodules. In previous studies, the investigators had taken the approach of methylation profiling by high throughput bisulfite DNA sequencing in tissue samples to identify specific methylation signatures. The investigators had learned methylation patterns that differentiate malignant vs. benign lesions from tissue samples by in-depth data mining, and then used pattern matching to classify plasma samples. In this study, the investigators are going to validate the efficacy of ctDNA methylation test for diagnosing early lung cancer by comparing results of the pre-surgery ctDNA methylation test with the post-surgery pathology.

Detailed description

This is a prospective, multi-center, observational cohort study and seeks to enroll 1230 participants with pulmonary nodules 5-30mm in diameter. The assay analyzes the ctDNA methylation profiles of lung cancer-specific biomarkers non-invasively using whole blood specimens collected before invasive surgery. The performance characteristics(sensitivity and specificity) of the pre-surgery ctDNA methylation test for detection of early lung cancer is evaluated in comparison to post-surgery pathology.

Interventions

DIAGNOSTIC_TESTCirculating Tumor DNA Methylation Test

Methylation profiling by high-throughput bisulfite DNA sequencing in blood sample to differentiate benign and malignant pulmonary nodules

Sponsors

AnchorDx Medical Co., Ltd.
CollaboratorINDUSTRY
First Affiliated Hospital, Sun Yat-Sen University
CollaboratorOTHER
Nanfang Hospital, Southern Medical University
CollaboratorOTHER
Central South University
CollaboratorOTHER
Xiangya Hospital of Central South University
CollaboratorOTHER
West China Hospital
CollaboratorOTHER
Qilu Hospital of Shandong University
CollaboratorOTHER
The Second Hospital University of South China
CollaboratorOTHER
Shenzhen People's Hospital
CollaboratorOTHER
The Fourth Affiliated Hospital of Harbin Medical University
CollaboratorOTHER
Peking University Cancer Hospital & Institute
CollaboratorOTHER
Xuanwu Hospital, Beijing
CollaboratorOTHER
Anhui Chest Hospital
CollaboratorOTHER
The First Affiliated Hospital with Nanjing Medical University
CollaboratorOTHER
The First Affiliated Hospital of Guangzhou Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years old or above * single pulmonary nodule found by CT scan. * the diameter of the pulmonary nodule is between 5mm to 30mm. * plan to accept pneumonectomy due to the pulmonary nodule. * without any sign of lymphatic or distant metastasis. * agree to sign informed consent.

Exclusion criteria

* pregnant or lactating women. * the diameter of the pulmonary nodule is more than 30mm * there are 2 or more pulmonary nodules in one single patient. * any sign of lymphatic or distant metastasis

Design outcomes

Primary

MeasureTime frameDescription
The diagnostic performance of the blood-based assay for differentiating benign and malignant pulmonary nodules early using circulating tumor DNA (ctDNA) methylation analysis by next-generation sequencing (NGS)1 yearThe efficacy of the blood-based ctDNA methylation assay comparing with pathologic diagnosis, the gold standard, including sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV).

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 16, 2026